Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLUENASDAQ:LFCRNASDAQ:MGXNASDAQ:PVLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$5.18+1.9%$4.38$3.21▼$12.40$318.25M1.4672,592 shs193,619 shsLFCRLifecore Biomedical$6.93+1.0%$6.51$3.68▼$7.99$256.58M0.65239,480 shs12,658 shsMGXMetagenomi$1.51-4.1%$1.60$1.23▼$6.90$56.07M-0.33799,258 shs335,252 shsPVLAPalvella Therapeutics$25.75-1.8%$23.51$6.20▼$29.27$284.69M-0.168,623 shs15,037 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+3.25%+9.48%+23.60%-23.49%+26.37%LFCRLifecore Biomedical+1.18%-0.15%-1.58%+6.69%+16.27%MGXMetagenomi-5.99%-11.30%+3.63%-23.41%-75.62%PVLAPalvella Therapeutics-1.50%+7.32%+15.20%-9.55%+2,622,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLUEMonte Rosa Therapeutics2.013 of 5 stars3.40.00.00.02.23.30.6LFCRLifecore Biomedical1.6309 of 5 stars2.32.00.00.01.44.20.6MGXMetagenomi2.2172 of 5 stars3.53.00.00.02.51.70.0PVLAPalvella Therapeutics4.0378 of 5 stars4.60.00.00.03.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLUEMonte Rosa Therapeutics 2.75Moderate Buy$15.50199.40% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.0015.41% UpsideMGXMetagenomi 3.00Buy$13.00763.79% UpsidePVLAPalvella Therapeutics 3.13Buy$46.2979.75% UpsideCurrent Analyst Ratings BreakdownLatest MGX, GLUE, PVLA, and LFCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.005/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.005/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.004/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.004/3/2025MGXMetagenomiHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $7.004/1/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.003/26/2025PVLAPalvella TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.003/25/2025PVLAPalvella TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.003/24/2025PVLAPalvella TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLUEMonte Rosa Therapeutics$159.49M2.00N/AN/A$3.58 per share1.45LFCRLifecore Biomedical$130.31M1.97N/AN/A$0.37 per share18.74MGXMetagenomi$45.26M1.24N/AN/AN/A∞PVLAPalvella Therapeutics$42.81M6.65N/AN/A$21.66 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLUEMonte Rosa Therapeutics-$135.35M$0.08N/AN/AN/AN/A-62.68%-38.83%8/14/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-12.52%-315.23%-12.74%8/15/2025 (Estimated)MGXMetagenomi-$68.25M-$2.11N/AN/AN/A-134.27%-43.23%-18.86%8/13/2025 (Estimated)PVLAPalvella Therapeutics-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%8/13/2025 (Estimated)Latest MGX, GLUE, PVLA, and LFCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/13/2025Q1 2025MGXMetagenomi-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 million4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 million3/20/2025Q4 2024GLUEMonte Rosa Therapeutics-$0.37$0.23+$0.60$0.23$43.73 million$14.00 million3/17/2025Q4 2024MGXMetagenomi-$0.62-$0.63-$0.01-$0.63$13.18 million$9.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLUEMonte Rosa TherapeuticsN/A6.036.03LFCRLifecore Biomedical9.212.321.21MGXMetagenomiN/A6.186.18PVLAPalvella TherapeuticsN/A4.824.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLUEMonte Rosa Therapeutics79.96%LFCRLifecore Biomedical83.36%MGXMetagenomiN/APVLAPalvella Therapeutics40.11%Insider OwnershipCompanyInsider OwnershipGLUEMonte Rosa Therapeutics6.90%LFCRLifecore Biomedical32.20%MGXMetagenomi17.80%PVLAPalvella Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLUEMonte Rosa Therapeutics9061.51 million57.44 millionOptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionableMGXMetagenomi23637.38 millionN/AN/APVLAPalvella TherapeuticsN/A11.06 million10.50 millionN/AMGX, GLUE, PVLA, and LFCR HeadlinesRecent News About These CompaniesCantor Fitzgerald Comments on PVLA FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comPalvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic MalformationsJune 9 at 7:52 AM | quiverquant.comPalvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsJune 9 at 7:30 AM | globenewswire.comCitadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)June 9 at 3:09 AM | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJune 8 at 5:17 AM | marketbeat.comToronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)June 2, 2025 | marketbeat.comPalvella Therapeutics Advances in Rare Skin Disease TherapiesMay 31, 2025 | tipranks.comPalvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial OfficerMay 27, 2025 | globenewswire.comToronto Dominion Bank Takes Position in Palvella Therapeutics (NASDAQ:PVLA)May 27, 2025 | marketbeat.comCantor Fitzgerald Predicts PVLA FY2025 EarningsMay 23, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Invests $7.85 Million in Palvella Therapeutics (NASDAQ:PVLA)May 23, 2025 | marketbeat.comCresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)May 20, 2025 | marketbeat.comSuvretta Capital Management LLC Takes $8.57 Million Position in Palvella Therapeutics (NASDAQ:PVLA)May 19, 2025 | marketbeat.comWhy Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%May 16, 2025 | aaii.comPromising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market PositionMay 16, 2025 | tipranks.comPalvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...May 16, 2025 | finance.yahoo.comPalvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by AnalystsMay 16, 2025 | marketbeat.comQ1 2025 Palvella Therapeutics Inc Earnings Call TranscriptMay 16, 2025 | gurufocus.comPalvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finanznachrichten.dePalvella Therapeutics: Q1 Earnings SnapshotMay 15, 2025 | timesunion.comPromising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN PlatformMay 15, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGX, GLUE, PVLA, and LFCR Company DescriptionsMonte Rosa Therapeutics NASDAQ:GLUE$5.18 +0.10 (+1.91%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Lifecore Biomedical NASDAQ:LFCR$6.93 +0.07 (+1.05%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Metagenomi NASDAQ:MGX$1.50 -0.07 (-4.14%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Palvella Therapeutics NASDAQ:PVLA$25.75 -0.48 (-1.83%) As of 10:52 AM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Will Warner Bros. Discovery’s Split Produce Double the Upside? Is a Summer Slowdown Ahead for Microsoft Stock? CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
